Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 55

Sort by

Sort Order Select

Journal Articles

Abstract 4297: Targeting metabolic dysfunction in prostate cancer: the anti-proliferative effects of ql47 through inhibition of dlat

Grace Nirmala Jesuthankaraj, August John, Huanyao Gao, Arun Kanakkanthara, Richard Weinshilboum, Liewei Wang

Cancer Res (2025) 85 (8_Supplement_1): 4297.

https://doi.org/10.1158/1538-7445.AM2025-4297

Published: 21 April 2025

View articletitled, Abstract 4297: Targeting metabolic dysfunction in prostate cancer: the anti-proliferative effects of ql47 through inhibition of dlat

Journal Articles

Abstract 2429: A multi-modal learning framework to integrate digital pathology image and multi-omics data in breast cancer

Naresh Prodduturi, Xiaojia Tang, Hamid R. Tizhoosh, Kevin J. Thompson, Richard Weinshilboum, Karthik V. Giridhar, Judy C. Boughey, Eric W. Klee, Liewei Wang, Matthew P. Goetz, Vera Suman, Krishna R. Kalari

Cancer Res (2025) 85 (8_Supplement_1): 2429.

https://doi.org/10.1158/1538-7445.AM2025-2429

Published: 21 April 2025

View articletitled, Abstract 2429: A multi-modal learning framework to integrate digital pathology image and multi-omics data in breast cancer

Journal Articles

Abstract 5658: Overcoming resistance in mCRPC: drug discovery using PDX models and high-throughput drug screening

Irene Marín-Goñi, Huanyao Gao, Joachim L. Petit, Shreya Indulkar, Adam M. Kase, Cassandra N. Moore, Krishna R. Kalari, Michael T. Barrett, Richard Weinshilboum, Winston Tan, John A. Copland, Liewei Wang

Cancer Res (2025) 85 (8_Supplement_1): 5658.

https://doi.org/10.1158/1538-7445.AM2025-5658

Published: 21 April 2025

View articletitled, Abstract 5658: Overcoming resistance in mCRPC: drug discovery using PDX models and high-throughput drug screening

Journal Articles

Abstract 4563: Ferroptotic mechanism of drug induced toxicity of PARPi and AurKi in prostate cancer

August John, Kuntian Luo, Zhenkun Lou, Liewei Wang

Cancer Res (2024) 84 (6_Supplement): 4563.

https://doi.org/10.1158/1538-7445.AM2024-4563

Published: 22 March 2024

View articletitled, Abstract 4563: Ferroptotic mechanism of drug induced toxicity of PARPi and AurKi in prostate cancer

Journal Articles

Bayesian Machine Learning Enables Identification of Transcriptional Network Disruptions Associated with Drug-Resistant Prostate Cancer

Charles Blatti, Jesús de la Fuente, Huanyao Gao, Irene Marín-Goñi, Zikun Chen, Sihai D. Zhao, Winston Tan, Richard Weinshilboum, Krishna R. Kalari, Liewei Wang, Mikel Hernaez

Cancer Res (2023) 83 (8): 1361–1380.

https://doi.org/10.1158/0008-5472.CAN-22-1910

Published: 14 April 2023

View articletitled, Bayesian Machine Learning Enables Identification of Transcriptional Network Disruptions Associated with Drug-Resistant Prostate Cancer

Includes: Supplementary data

Journal Articles

Abstract 1689: The role of circular RNAs in triple negative breast cancer and chemotherapy resistance

Xiyin Wang, Michael J. Emch, Xiaojia Tang, Jia Yu, Krishna R. Kalari, Liewei Wang, Matthew P. Goetz, John R. Hawse

Cancer Res (2023) 83 (7_Supplement): 1689.

https://doi.org/10.1158/1538-7445.AM2023-1689

Published: 04 April 2023

View articletitled, Abstract 1689: The role of circular RNAs in triple negative breast cancer and chemotherapy resistance

Journal Articles

Abstract 4290: ReCorDE: A novel computational framework to discover potential combinations of anti-cancer drugs

Emily T. Ghose, August John, Huanyao Gao, Krishna R. Kalari, Liewei Wang

Cancer Res (2023) 83 (7_Supplement): 4290.

https://doi.org/10.1158/1538-7445.AM2023-4290

Published: 04 April 2023

View articletitled, Abstract 4290: ReCorDE: A novel computational framework to discover potential combinations of anti-cancer drugs

Journal Articles

Abstract OT1-04-02: Anastrozole dose escalation for optimal estrogen suppression in postmenopausal early stage breast cancer: A prospective trial

Tufia C. Haddad, Vera Suman, Karthik V. Giridhar, Alvaro Moreno-Aspitia, Donald Northfelt, Brenda Ernst, Kostandinos Sideras, Ciara C. O’Sullivan, Ravinder Singh, Zeruesenay Desta, Jodi Taraba, Barbara Goodnature, Matthew P. Goetz, Liewei Wang, James N. Ingle

Cancer Res (2023) 83 (5_Supplement): OT1-04-02.

https://doi.org/10.1158/1538-7445.SABCS22-OT1-04-02

Published: 01 March 2023

View articletitled, Abstract OT1-04-02: Anastrozole dose escalation for optimal estrogen suppression in postmenopausal early stage breast cancer: A prospective trial

Journal Articles

Pharmacological Targeting of Androgen Receptor Elicits Context-Specific Effects in Estrogen Receptor–Positive Breast Cancer

Lixuan Wei, Huanyao Gao, Jia Yu, Huan Zhang, Thanh Thanh L. Nguyen, Yayun Gu, Marie R. Passow, Jodi M. Carter, Bo Qin, Judy C. Boughey, Matthew P. Goetz, Richard M. Weinshilboum, James N. Ingle, Liewei Wang

Cancer Res (2023) 83 (3): 456–470.

https://doi.org/10.1158/0008-5472.CAN-22-1016

Published: 03 February 2023

View articletitled, Pharmacological Targeting of Androgen Receptor Elicits Context-Specific Effects in Estrogen Receptor–Positive Breast Cancer

Includes: Supplementary data

Journal Articles

Abstract PD1-03: Estrogen receptor is a target of enzalutamide in ER+ breast cancer

Lixuan Wei, Jia Yu, Huanyao Gao, Huan Zhang, Thanh Nguyen, Yayun Gu, Richard M. Weinshilboum, James N. Ingle, Liewei Wang

Cancer Res (2022) 82 (4_Supplement): PD1-03.

https://doi.org/10.1158/1538-7445.SABCS21-PD1-03

Published: 15 February 2022

View articletitled, Abstract PD1-03: Estrogen receptor is a target of enzalutamide in ER+ breast cancer

Journal Articles

Abstract P4-01-03: Multiomics data reveal novel biomarkers for CDK4/6 resistance

Cancer Res (2022) 82 (4_Supplement): P4-01-03.

https://doi.org/10.1158/1538-7445.SABCS21-P4-01-03

Published: 15 February 2022

View articletitled, Abstract P4-01-03: Multiomics data reveal novel biomarkers for CDK4/6 resistance

Journal Articles

Abstract OT2-19-05: A phase I/II trial of abemaciclib and T-DM1 in women and men with HER2-positive advanced or metastatic breast cancer that has progressed on treatment with a taxane, trastuzumab and pertuzumab (THP) (ACCRU-BR-1801)

Cancer Res (2022) 82 (4_Supplement): OT2-19-05.

https://doi.org/10.1158/1538-7445.SABCS21-OT2-19-05

Published: 15 February 2022

View articletitled, Abstract OT2-19-05: A phase I/II trial of abemaciclib and T-DM1 in women and men with HER2-positive advanced or metastatic breast cancer that has progressed on treatment with a taxane, trastuzumab and pertuzumab (THP) (ACCRU-BR-1801)

Journal Articles

Abstract P5-13-22: Serum thymidine kinase 1 activity (TKa) levels and progression-free survival (PFS) in patients (pts) with hormone receptor positive (HR+) HER2-negative metastatic breast cancer (MBC) on palbociclib (Pb) and endocrine therapy (ET)

Cancer Res (2022) 82 (4_Supplement): P5-13-22.

https://doi.org/10.1158/1538-7445.SABCS21-P5-13-22

Published: 15 February 2022

View articletitled, Abstract P5-13-22: Serum thymidine kinase 1 activity (TKa) levels and progression-free survival (PFS) in patients (pts) with hormone receptor positive (HR+) HER2-negative metastatic breast cancer (MBC) on palbociclib (Pb) and endocrine therapy (ET)

Journal Articles

Abstract P4-01-05: Multi-omics data shows downregulation of mismatch repair, purin and tublin pathways in AR-negative triple-negative chemotherapy-resistant tumors

Krishna R Kalari, Vera J Suman, Xiaojia Tang, Jason P Sinnwell, Kevin J Thompson, Peter T Vedell, Jodi M Carter, Sarah A McLaughlin, Alvaro Moreno Aspitia, Donald W Northfelt, Richard J Gray, Richard Weinshilboum, Liewei Wang, Judy C Boughey, Matthew Goetz

Cancer Res (2022) 82 (4_Supplement): P4-01-05.

https://doi.org/10.1158/1538-7445.SABCS21-P4-01-05

Published: 15 February 2022

View articletitled, Abstract P4-01-05: Multi-omics data shows downregulation of mismatch repair, purin and tublin pathways in AR-negative triple-negative chemotherapy-resistant tumors

Journal Articles

Abstract P5-01-07: Patient-derived xenografts (PDXs) generated from hormone receptor-positive breast cancer (BC) before and after cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) treatment: Initial findings from the PROMISE study

Cancer Res (2022) 82 (4_Supplement): P5-01-07.

https://doi.org/10.1158/1538-7445.SABCS21-P5-01-07

Published: 15 February 2022

View articletitled, Abstract P5-01-07: Patient-derived xenografts (PDXs) generated from hormone receptor-positive breast cancer (BC) before and after cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) treatment: Initial findings from the PROMISE study

Journal Articles

Quantitative Analysis of Tyrosine Phosphorylation from FFPE Tissues Reveals Patient-Specific Signaling Networks

Ishwar N. Kohale, Danielle M. Burgenske, Ann C. Mladek, Katrina K. Bakken, Jenevieve Kuang, Judy C. Boughey, Liewei Wang, Jodi M. Carter, Eric B. Haura, Matthew P. Goetz, Jann N. Sarkaria, Forest M. White

Cancer Res (2021) 81 (14): 3930–3941.

https://doi.org/10.1158/0008-5472.CAN-21-0214

Published: 15 July 2021

View articletitled, Quantitative Analysis of Tyrosine Phosphorylation from FFPE Tissues Reveals Patient-Specific Signaling Networks

Includes: Supplementary data

Journal Articles

Inhibition of ATM Induces Hypersensitivity to Proton Irradiation by Upregulating Toxic End Joining

Qin Zhou, Michelle E. Howard, Xinyi Tu, Qian Zhu, Janet M. Denbeigh, Nicholas B. Remmes, Michael G. Herman, Chris J. Beltran, Jian Yuan, Patricia T. Greipp, Judy C. Boughey, Liewei Wang, Neil Johnson, Matthew P. Goetz, Jann N. Sarkaria, Zhenkun Lou, Robert W. Mutter

Cancer Res (2021) 81 (12): 3333–3346.

https://doi.org/10.1158/0008-5472.CAN-20-2960

Published: 15 June 2021

View articletitled, Inhibition of ATM Induces Hypersensitivity to Proton Irradiation by Upregulating Toxic End Joining

Includes: Supplementary data

Journal Articles

Abstract PS5-24: Novel genomic variants and pathways associated with baseline serum thymidine kinase 1 levels in HR-positive HER2-negative MBC patients commencing palbociclib and letrozole

Cancer Res (2021) 81 (4_Supplement): PS5-24.

https://doi.org/10.1158/1538-7445.SABCS20-PS5-24

Published: 15 February 2021

View articletitled, Abstract PS5-24: Novel genomic variants and pathways associated with baseline serum thymidine kinase 1 levels in HR-positive HER2-negative MBC patients commencing palbociclib and letrozole

Journal Articles

Abstract PS5-36: Computational modeling of androgen receptor (AR) and estrogen receptor as predictive biomarkers of response to AR agonists and antagonists

Lixuan Wei, Huanyao Gao, Jia Yu, Duan Liu, Huan Zhang, Thanh Nguyen, Marie R Passow, Jodi M Carter, Richard M Weinshilboum, James N Ingle, Liewei Wang

Cancer Res (2021) 81 (4_Supplement): PS5-36.

https://doi.org/10.1158/1538-7445.SABCS20-PS5-36

Published: 15 February 2021

View articletitled, Abstract PS5-36: Computational modeling of androgen receptor (AR) and estrogen receptor as predictive biomarkers of response to AR agonists and antagonists

Journal Articles

Abstract PD8-04: Antitumor activity of Z-endoxifen (ENDX) is mediated via PKCβ1-dependent ERα loss and cell cycle arrest in ERα-positive breast cancer

Swaathi Jayaraman, Mary J Kuffel, Krishna R Kalari, Kevin J Thompson, Xiaojia Tang, Vera J Suman, Elizabeth S Bruinsma, Ciara C O'Sullivan, Liewei Wang, Richard Weinshilboum, James N Ingle, John R Hawse, Matthew P Goetz

Cancer Res (2021) 81 (4_Supplement): PD8-04.

https://doi.org/10.1158/1538-7445.SABCS20-PD8-04

Published: 15 February 2021

View articletitled, Abstract PD8-04: Antitumor activity of Z-endoxifen (ENDX) is mediated via PKCβ1-dependent ERα loss and cell cycle arrest in ERα-positive breast cancer

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract 4297: Targeting metabolic dysfunction in prostate cancer: the anti-proliferative effects of ql47 through inhibition of dlat

Abstract 2429: A multi-modal learning framework to integrate digital pathology image and multi-omics data in breast cancer

Abstract 5658: Overcoming resistance in mCRPC: drug discovery using PDX models and high-throughput drug screening

Abstract 4563: Ferroptotic mechanism of drug induced toxicity of PARPi and AurKi in prostate cancer

Bayesian Machine Learning Enables Identification of Transcriptional Network Disruptions Associated with Drug-Resistant Prostate Cancer

Abstract 1689: The role of circular RNAs in triple negative breast cancer and chemotherapy resistance

Abstract 4290: ReCorDE: A novel computational framework to discover potential combinations of anti-cancer drugs

Abstract OT1-04-02: Anastrozole dose escalation for optimal estrogen suppression in postmenopausal early stage breast cancer: A prospective trial

Pharmacological Targeting of Androgen Receptor Elicits Context-Specific Effects in Estrogen Receptor–Positive Breast Cancer

Abstract PD1-03: Estrogen receptor is a target of enzalutamide in ER+ breast cancer

Abstract P4-01-03: Multiomics data reveal novel biomarkers for CDK4/6 resistance

Abstract OT2-19-05: A phase I/II trial of abemaciclib and T-DM1 in women and men with HER2-positive advanced or metastatic breast cancer that has progressed on treatment with a taxane, trastuzumab and pertuzumab (THP) (ACCRU-BR-1801)

Abstract P5-13-22: Serum thymidine kinase 1 activity (TKa) levels and progression-free survival (PFS) in patients (pts) with hormone receptor positive (HR+) HER2-negative metastatic breast cancer (MBC) on palbociclib (Pb) and endocrine therapy (ET)

Abstract P4-01-05: Multi-omics data shows downregulation of mismatch repair, purin and tublin pathways in AR-negative triple-negative chemotherapy-resistant tumors

Abstract P5-01-07: Patient-derived xenografts (PDXs) generated from hormone receptor-positive breast cancer (BC) before and after cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) treatment: Initial findings from the PROMISE study

Quantitative Analysis of Tyrosine Phosphorylation from FFPE Tissues Reveals Patient-Specific Signaling Networks

Inhibition of ATM Induces Hypersensitivity to Proton Irradiation by Upregulating Toxic End Joining

Abstract PS5-24: Novel genomic variants and pathways associated with baseline serum thymidine kinase 1 levels in HR-positive HER2-negative MBC patients commencing palbociclib and letrozole

Abstract PS5-36: Computational modeling of androgen receptor (AR) and estrogen receptor as predictive biomarkers of response to AR agonists and antagonists

Abstract PD8-04: Antitumor activity of Z-endoxifen (ENDX) is mediated via PKCβ1-dependent ERα loss and cell cycle arrest in ERα-positive breast cancer

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only